Published online Sep 26, 2023. doi: 10.12998/wjcc.v11.i27.6407
Peer-review started: August 1, 2023
First decision: August 16, 2023
Revised: August 22, 2023
Accepted: August 29, 2023
Article in press: August 29, 2023
Published online: September 26, 2023
Processing time: 50 Days and 15.7 Hours
Core Tip: This study aimed to investigate the potential association of serum thyroglobulin (Tg) and thyroid-stimulating hormone (TSH) levels with the risk of thyroid cancer among patients undergoing thyroid nodule surgery. Moreover, we retrospectively analyzed the clinical data and laboratory results of 130 patients who underwent thyroid nodule surgery. Their preoperative Tg and TSH levels were recorded, and subsequent histopathological examinations were conducted during follow-up to determine the presence of thyroid cancer. These results indicated that serum Tg levels were significantly correlated with the risk of thyroid cancer (P < 0.05), suggesting that high Tg levels are associated with an increased likelihood of developing thyroid cancer. However, no significant correlation was observed between serum TSH levels and thyroid cancer risk (P > 0.05). In conclusion, this study highlighted that in patients undergoing thyroid nodule surgery, serum Tg can serve as an important biomarker for assessing the risk of thyroid cancer, whereas serum TSH does not exhibit a significant predictive relationship.